Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585125 | 0.87 | XDH (0.38) | XDHAAK1ALDH1A1HPGDAR | |
| SCHEMBL12128121 | 0.85 | KDM4E (0.40) | XDHAAK1ALDH1A1ENPP2AR | |
| SCHEMBL8216484 | 0.83 | XDH (0.43) | XDHALDH1A1HPGDENPP2AR | |
| SCHEMBL3591595 | 0.82 | MGLL (0.42) | XDHAAK1AR | |
| SCHEMBL3593175 | 0.81 | NPC1 (0.41) | ALDH1A1ENPP2ARNPC1RAB9A | |
| SCHEMBL3590939 | 0.81 | XDH (0.51) | XDHALDH1A1HPGDENPP2AR | |
| SCHEMBL29951250 | 0.81 | ALDH1A1 (0.50) | XDHALDH1A1HPGDAR | |
| SCHEMBL12127975 | 0.79 | ALDH1A1 (0.56) | XDHALDH1A1HPGDAR | |
| SCHEMBL1331417 | 0.79 | XDH (0.52) | XDH | |
| SCHEMBL3599508 | 0.79 | ADRB2 (0.43) | ALDH1A1ENPP2ARNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-07 | — | — | US | disclosed |
| EP-2128136-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | Nippon Zoki Pharmaceutical Co., Ltd. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004459-A1 | 2-PHENYLNICOTINIC ACID DERIVATIVE | XDH, NUDT1, PNPO | XDH 1/4885AAK1 1888/4885ALDH1A1 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.